Please login to the form below

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

atopic dermatitis and asthma therapy Dupixent (dupilumab) and Ablynx’ rare blood disorder product Cablivi (caplacizumab).

Sanofi exits R&D pact with Alnylam on rare disease

Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).
Sanofi extends growth spurt thanks to Genzyme, Dupixent

from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP), which made its debut in Germany in October.
Sanofi gets US okay for $270,000 blood disorder drug Cablivi

The US approval – which comes a few months after Cablivi (caplacizumab) was cleared in the EU – if for the use of Cablivi in combination with plasma exchange and immunosuppressive therapy in
As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
Dupixent helps put Sanofi back on growth track

Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Deal Watch January 2018

bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Novo Nordisk target Ablynx reshuffles its board

lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...